Molecular pain
Cure8 research brief
Why This Matters
The study points to the TREM1/DAP12 microglial pathway as a possible mechanism for visceral pain in an IBD model and shows both electroacupuncture and a TREM1 inhibitor reduced pain behaviors and EEG abnormalities in rats, which could guide future preclinical-to-clinical research.
Who Should Pay Attention
Researchers, preclinical investigators, clinicians interested in neuroimmune mechanisms of IBD pain, and those studying complementary therapies like acupuncture.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a preclinical (rat) study using TNBS to induce colitis and visceral hypersensitivity. Researchers measured behavioral pain responses, disease activity index, spinal TREM1/DAP12 expression and microglial markers, and cortical EEG power spectra.
Both EA at ST36/ST37 and pharmacologic TREM1 blockade were reported to reduce pain behaviors and normalize EEG rhythms; the combination produced greater delta suppression. The paper supports TREM1/DAP12-driven neuroinflammation as a potential target for visceral pain and presents EA as a nonpharmacologic intervention that may act on the same pathway.
These findings are mechanistic and exploratory — they do not demonstrate safety or efficacy in humans.
Keep In Mind
This is an abstract-level report of a preclinical (rat) experiment using TNBS-induced colitis; findings are exploratory and not evidence of clinical benefit in people.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMolecular pain
AuthorsWang K, Deng D, Yu R +5 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
From mechanical stress to mesenteric adipocyte dysfunction in Crohn's disease: an essential role of Piezo1-mediated mitochondrial calcium overload.
If confirmed and translated, targeting the Piezo1–mPTP pathway could lead to new treatments that reduce inflammatory signaling from diseased mesenteric fat in Crohn’s disease. The study also provides a clearer...
Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
Design, Synthesis, and Biological Evaluation of Novel Arylethanone Oxime Ether Derivatives as Potent S1PR1 Agonists for Ulcerative Colitis Therapy
S1PR1 drugs (S1P modulators) are an important drug class for IBD; a selective S1PR1 agonist with less S1PR3 activity could mean fewer heart-related side effects. This preclinical work highlights a possible new candidate...